These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33590909)

  • 1. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
    Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
    Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Most colitis associated carcinomas lack expression of LGR5: a preliminary study with implications for unique pathways of carcinogenesis compared to sporadic colorectal carcinoma.
    Iwaya M; Ota H; Nakajima T; Uehara T; Riddell R; Conner J
    BMC Cancer; 2021 Feb; 21(1):119. PubMed ID: 33541282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zolbetuximab: First Approval.
    Keam SJ
    Drugs; 2024 Aug; 84(8):977-983. PubMed ID: 38967717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in morphology and immunohistochemistry of Crohn's disease-associated small bowel neoplasms: implications of Claudin 18 and Cadherin 17 expression for tumor-targeted immunotherapies.
    Iwaya M; Kodama M; Abe K; Maeda K; Nakajima T; Uehara T; Nishio R; Yamana T; Riddell R; Ota H
    Virchows Arch; 2024 Aug; ():. PubMed ID: 39164422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
    Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
    Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
    Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
    J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma.
    Liu X; Goldblum JR; Zhao Z; Landau M; Heald B; Pai R; Lin J
    Am J Surg Pathol; 2012 Aug; 36(8):1228-33. PubMed ID: 22790862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
    Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
    Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
    Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
    Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
    Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
    BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy.
    Maeda K; Uehara T; Hosoda W; Kuraishi Y; Ota H
    Pathol Res Pract; 2024 Oct; 262():155537. PubMed ID: 39178509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
    Ogawa H; Abe H; Yagi K; Seto Y; Ushiku T
    Gastric Cancer; 2024 Jul; 27(4):802-810. PubMed ID: 38724721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
    Rogers JE; Ajani J
    Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases.
    Coati I; Lotz G; Fanelli GN; Brignola S; Lanza C; Cappellesso R; Pellino A; Pucciarelli S; Spolverato G; Guzzardo V; Munari G; Zaninotto G; Scarpa M; Mastracci L; Farinati F; Realdon S; Pilati P; Lonardi S; Valeri N; Rugge M; Kiss A; Loupakis F; Fassan M
    Br J Cancer; 2019 Jul; 121(3):257-263. PubMed ID: 31235864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.